The KEYNOTE-024 trial was the first to show that first-line PD-1 monoclonal antibody monotherapy in EGFR/ALK wild-type, PD-L1 TPS 50% of newly treated advanced NSCLC patients showed significantly enhance overall survival relative to chemotherapy. Here, ALK is linked to non-small cell lung carcinoma.